NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Forecast, Price & News

$1.58

-0.01 (-0.63%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.58
▼
$1.62
50-Day Range: $1.55
▼
$2.01
52-Week Range: $1.53
▼
$3.07

Volume: 98,578 shs
Average Volume: 183,907 shs
Market Capitalization: $90.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.75

aTyr Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 1,213.3% Upside
$20.75 Price Target
Short Interest: Healthy
0.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.01) to ($1.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

278th out of 970 stocks

Biological Products, Except Diagnostic Industry

44th out of 157 stocks

3.4

Analyst's Opinion

Consensus Rating
aTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.75, aTyr Pharma has a forecasted upside of 1,213.3% from its current price of $1.58.
Amount of Analyst Coverage
aTyr Pharma has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.72% of the outstanding shares of aTyr Pharma have been sold short.
Short Interest Ratio / Days to Cover
aTyr Pharma has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in aTyr Pharma has recently decreased by 5.85%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
aTyr Pharma does not currently pay a dividend.
Dividend Growth
aTyr Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIFE.

2.6

News and Social Media Coverage

News Sentiment
aTyr Pharma has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for aTyr Pharma this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for LIFE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, aTyr Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.14% of the stock of aTyr Pharma is held by insiders.
Percentage Held by Institutions
62.53% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for aTyr Pharma are expected to decrease in the coming year, from ($1.01) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of aTyr Pharma is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of aTyr Pharma is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
aTyr Pharma has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About aTyr Pharma (NASDAQ:LIFE) Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

LIFE Price History

30 days | 90 days | 365 days | Advanced Chart

LIFE Stock News Headlines

September 28, 2023 | markets.businessinsider.com

Buy Rating for aTyr Pharma: Promising Developments in Efzofitimod Clinical Trials and Potential Expansion Opportunities

September 26, 2023 | markets.businessinsider.com

aTyr Pharma (LIFE) Gets a Buy from Piper Sandler

September 30, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 25, 2023 | americanbankingnews.com

Reviewing AlloVir (NASDAQ:ALVR) and aTyr Pharma (NASDAQ:LIFE)

September 25, 2023 | americanbankingnews.com

FY2025 EPS Estimates for aTyr Pharma, Inc. Raised by Analyst (NASDAQ:LIFE)

September 23, 2023 | americanbankingnews.com

aTyr Pharma (NASDAQ:LIFE) Stock Rating Reaffirmed by HC Wainwright

September 23, 2023 | americanbankingnews.com

aTyr Pharma, Inc. (NASDAQ:LIFE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Genfit SA (GNFT) and Boston Scientific (BSX)

September 30, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 11, 2023 | finance.yahoo.com

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

August 30, 2023 | finance.yahoo.com

Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)

August 30, 2023 | finance.yahoo.com

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

August 24, 2023 | finance.yahoo.com

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 11, 2023 | markets.businessinsider.com

JonesTrading Sticks to Its Buy Rating for aTyr Pharma (LIFE)

August 9, 2023 | finance.yahoo.com

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

August 2, 2023 | msn.com

Atyr Pharma (LIFE) Price Target Increased by 8.21% to 21.76

July 20, 2023 | finance.yahoo.com

aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56%

July 5, 2023 | msn.com

Oppenheimer Downgrades Atyr Pharma (LIFE)

July 5, 2023 | msn.com

aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst

June 28, 2023 | markets.businessinsider.com

7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023

June 22, 2023 | finance.yahoo.com

European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis

June 20, 2023 | finance.yahoo.com

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

June 6, 2023 | finance.yahoo.com

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

May 25, 2023 | finance.yahoo.com

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

May 23, 2023 | nasdaq.com

HC Wainwright & Co. Reiterates Atyr Pharma (LIFE) Buy Recommendation

May 23, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for aTyr Pharma

May 23, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for aTyr Pharma (LIFE)

See More Headlines

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Company Calendar

Last Earnings: 8/09/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NASDAQ:LIFE
CUSIP: 53217V10
CIK: 1339970
Web: www.atyrpharma.com
Phone: (858) 731-8389
Fax: 858-731-8394
Employees: 65
Year Founded: 2005

Price Target and Rating

Average Stock Price Forecast: $20.75
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +1,213.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,340,000.00
Net Margins: N/A
Pretax Margin: -433.87%
Return on Equity: -49.51%
Return on Assets: -39.06%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 9.25
Quick Ratio: 9.25

Sales & Book Value

Annual Sales: $10.39 million
Price / Sales: 8.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.42 per share
Price / Book: 0.65

Miscellaneous

Outstanding Shares: 57,050,000
Free Float: 55,255,000
Market Cap: $90.14 million
Optionable: Optionable
Beta: 1.26

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Sanjay S. Shukla M.D. (Age 51)
M.S., Pres, CEO & Director
Comp: $795.48k

Ms. Jill M. Broadfoot (Age 61)
Chief Financial Officer
Comp: $556.62k

Ms. Nancy E. Denyes Krueger (Age 55)
Gen. Counsel & Corp. Sec.
Comp: $532.13k

Xiang-Lei Yang Ph.D.
Founder

Ms. Ashlee Dunston
Director of Investor Relations & Corp. Communications

Mr. Peter Villiger
VP of Corp. Devel.

Ms. Danielle Campbell
VP of Human Resource

Dr. Leslie Nangle Ph.D.
VP of Research

Dr. Ying J. Buechler Ph.D.
Exec. Director of Biologics Devel. & Manufacturing

Dr. David J. King (Age 64)
Scientific Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LIFE shares.
View LIFE analyst ratings or view top-rated stocks.
What is aTyr Pharma's stock price forecast for 2023?: 6 Wall Street research analysts have issued 1 year price objectives for aTyr Pharma's shares. Their LIFE share price forecasts range from $9.00 to $35.00. On average, they predict the company's stock price to reach $20.75 in the next twelve months. This suggests a possible upside of 1,213.3% from the stock's current price.
View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts.
How have LIFE shares performed in 2023?: aTyr Pharma's stock was trading at $2.19 at the beginning of 2023. Since then, LIFE shares have decreased by 27.9% and is now trading at $1.58.
View the best growth stocks for 2023 here.
Are investors shorting aTyr Pharma?: aTyr Pharma saw a decrease in short interest in September. As of September 15th, there was short interest totaling 411,800 shares, a decrease of 5.9% from the August 31st total of 437,400 shares. Based on an average daily trading volume, of 256,600 shares, the short-interest ratio is presently 1.6 days.
View aTyr Pharma's Short Interest.
When is aTyr Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LIFE earnings forecast.
How were aTyr Pharma's earnings last quarter?: aTyr Pharma, Inc. (NASDAQ:LIFE) announced its quarterly earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05.
When did aTyr Pharma's stock split?: aTyr Pharma's stock reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?: 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of aTyr Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).
When did aTyr Pharma IPO?: (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
What is aTyr Pharma's stock symbol?: aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How do I buy shares of aTyr Pharma?: Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is aTyr Pharma's stock price today?: One share of LIFE stock can currently be purchased for approximately $1.58.
How much money does aTyr Pharma make?: aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $90.14 million and generates $10.39 million in revenue each year. The biotechnology company earns $-45,340,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis.
How can I contact aTyr Pharma?: aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.

This page (NASDAQ:LIFE) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial